| __timestamp | Teva Pharmaceutical Industries Limited | Ultragenyx Pharmaceutical Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 5078000000 | 10811000 |
| Thursday, January 1, 2015 | 4717000000 | 33001000 |
| Friday, January 1, 2016 | 5096000000 | 64936000 |
| Sunday, January 1, 2017 | 4986000000 | 99909000 |
| Monday, January 1, 2018 | 4214000000 | 127724000 |
| Tuesday, January 1, 2019 | 3806000000 | 161524000 |
| Wednesday, January 1, 2020 | 3671000000 | 182933000 |
| Friday, January 1, 2021 | 3528000000 | 219982000 |
| Saturday, January 1, 2022 | 3445000000 | 278139000 |
| Sunday, January 1, 2023 | 3498000000 | 309799000 |
| Monday, January 1, 2024 | 3702000000 |
Unlocking the unknown
In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. This analysis compares the SG&A trends of Teva Pharmaceutical Industries Limited and Ultragenyx Pharmaceutical Inc. from 2014 to 2023.
Teva, a global leader, saw a significant reduction in SG&A expenses, dropping approximately 32% from 2014 to 2023. This decline reflects strategic cost-cutting measures and operational efficiencies. In contrast, Ultragenyx, a smaller biotech firm, experienced a dramatic increase of over 2,700% in the same period, indicative of its aggressive expansion and investment in research and development.
These contrasting trends highlight the different strategic priorities of established versus emerging pharmaceutical companies. While Teva focuses on streamlining operations, Ultragenyx is investing heavily in growth, positioning itself for future breakthroughs.
SG&A Efficiency Analysis: Comparing Johnson & Johnson and Ultragenyx Pharmaceutical Inc.
Cost Management Insights: SG&A Expenses for Amgen Inc. and Teva Pharmaceutical Industries Limited
Who Optimizes SG&A Costs Better? Regeneron Pharmaceuticals, Inc. or Ultragenyx Pharmaceutical Inc.
Breaking Down SG&A Expenses: argenx SE vs Teva Pharmaceutical Industries Limited
SG&A Efficiency Analysis: Comparing Alnylam Pharmaceuticals, Inc. and Ultragenyx Pharmaceutical Inc.
Cost Management Insights: SG&A Expenses for Teva Pharmaceutical Industries Limited and CRISPR Therapeutics AG
Teva Pharmaceutical Industries Limited vs Arrowhead Pharmaceuticals, Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Teva Pharmaceutical Industries Limited or Supernus Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Ultragenyx Pharmaceutical Inc.
Selling, General, and Administrative Costs: Viatris Inc. vs Ultragenyx Pharmaceutical Inc.
Alkermes plc or Ultragenyx Pharmaceutical Inc.: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for Ultragenyx Pharmaceutical Inc. and BioCryst Pharmaceuticals, Inc.